The 2026 Biologics Wave: Which Innovations Will Break Through? Contract Pharma BREAKING NEWS: HHS @seckennedy just announced that the FDA is taking a step toward restoring science based access by removing 12 peptides from Category 2. FDA is moving them to an independent scientific Important Update on FDA Changes Concerning Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Launches Framework to Accelerate Individualized Therapies for Ultra Rare Diseases 2026 OncoDaily Nine Anticipated FDA Approvals for January 2026 Guideline Central